학술논문
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
Document Type
Article
Author
Source
In The Lancet Oncology December 2023 24(12):1359-1374
Subject
Language
ISSN
1470-2045